Expression of the Epigenetic factor BORIS (CTCFL) in the Human Genome

Journal of Translational Medicine

Ewa Carrier¹  Michael G Agadjanyan²  Chien-Shing Chen⁷  Doru T Alexandrescu⁸  Feridoun Karimi-Busheri⁴  Erik Woods⁶  Shelly Zacharias⁶  Steven F Josephs⁵  Anahit Ghochikyan³  Rosalia de Necochea-Campion¹ 

[1] Department of Medicine, University of California, San Diego, CA 92093, USA;Mechnikov Research Institute of Vaccine and Sera, Russian Academy of Medical Sciences, Moscow, 105064, Russia;Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA;NovaRX Corporation, Stem Cell Dept., San Diego, CA 92121, USA;Therinject LLC, San Diego, CA 92121, USA;RenovoCyte LLC, Indianapolis, IN 46202, USA;Division of Hematology and Oncology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA;Department of Dermatology, Georgetown Dermatology, Washington, DC 20017, USA

关键词: cancer immunotherapy;    protein partners;    epigenetic regulation;    CTCF;    BORIS;   

Others  :  1207805
DOI  :  10.1186/1479-5876-9-213

 received in 2011-07-07, accepted in 2011-12-14,  发布年份 2011

【 摘 要 】

BORIS, or CTCFL, the so called Brother of the Regulator of Imprinted Sites because of the extensive homology in the central DNA binding region of the protein to the related regulator, CTCF, is expressed in early gametogenesis and in multiple cancers but not in differentiated somatic cells. Thus it is a member of the cancer testes antigen group (CTAs). Since BORIS and CTCF target common DNA binding sites, these proteins function on two levels, the first level is their regulation via the methylation context of the DNA target site and the second level is their distinct and different epigenetic associations due to differences in the non-homologous termini of the proteins. The regulation on both of these levels is extensive and complex and the sphere of influence of each of these proteins is associated with vastly different cellular signaling processes. On the level of gene expression, BORIS has three known promoters and multiple spliced mRNAs which adds another level of complexity to this intriguing regulator. BORIS expression is observed in the majority of cancer tissues and cell lines analyzed up to today. The expression profile and essential role of BORIS in cancer make this molecule very attractive target for cancer immunotherapy. This review summarizes what is known about BORIS regarding its expression, structure, and function and then presents some theoretical considerations with respect to its genome wide influence and its potential for use as a vaccine for cancer immunotherapy.

【 授权许可】

   
2011 de Necochea-Campion et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Kalejs M, Erenpreisa J: Cancer/testis antigens and gametogenesis: a review and "brain-storming" session. Cancer Cell Int 2005, 5:4. BioMed Central Full Text
• [2]Hore TA, Deakin JE, Marshall Graves JA: The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes. PLoS Genet 2008, 4:e1000169.
• [3]Benton MJ: Early origins of modern birds and mammals: molecules vs. morphology. Bioessays 1999, 21:1043-1051.
• [4]Ellegren H: Molecular evolutionary genomics of birds. Cytogenet Genome Res 2007, 117:120-130.
• [5]Phillips JE, Corces VG: CTCF: master weaver of the genome. Cell 2009, 137:1194-1211.
• [6]Kouprina N, Noskov VN, Pavlicek A, Collins NK, Schoppee Bortz PD, Ottolenghi C, Loukinov D, Goldsmith P, Risinger JI, Kim JH, et al.: Evolutionary diversification of SPANX-N sperm protein gene structure and expression. PLoS One 2007, 2:e359.
• [7]Przytycka TM, Jothi R, Aravind L, Lipman DJ: Differences in evolutionary pressure acting within highly conserved ortholog groups. BMC Evol Biol 2008, 8:208. BioMed Central Full Text
• [8]Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, Barsov E, Strunnikov AV, Morse HC, Loukinov D, Lobanenkov V: The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One 5:e13872.
• [9]Klenova EM, Morse HC, Ohlsson R, Lobanenkov VV: The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 2002, 12:399-414.
• [10]Kang Y, Hong JA, Chen GA, Nguyen DM, Schrump DS: Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene 2007, 26:4394-4403.
• [11]Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H, Schrump DS, et al.: Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005, 65:7751-7762.
• [12]Suzuki T, Kosaka-Suzuki N, Pack S, Shin DM, Yoon J, Abdullaev Z, Pugacheva E, Morse HC, Loukinov D, Lobanenkov V: Expression of a testis-specific form of Gal3st1 (CST), a gene essential for spermatogenesis, is regulated by the CTCF paralogous gene BORIS. Mol Cell Biol 30:2473-2484.
• [13]Monk M, Hitchins M, Hawes S: Differential expression of the embryo/cancer gene ECSA(DPPA2), the cancer/testis gene BORIS and the pluripotency structural gene OCT4, in human preimplantation development. Mol Hum Reprod 2008, 14:347-355.
• [14]Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J, Lobanenkov V: Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res 2007, 35:7372-7388.
• [15]Ohlsson R, Renkawitz R, Lobanenkov V: CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 2001, 17:520-527.
• [16]van de Nobelen S, Rosa-Garrido M, Leers J, Heath H, Soochit W, Joosen L, Jonkers I, Demmers J, van der Reijden M, Torrano V, et al.: CTCF regulates the local epigenetic state of ribosomal DNA repeats. Epigenetics Chromatin 3:19.
• [17]Majumder P, Boss JM: DNA methylation dysregulates and silences the HLA-DQ locus by altering chromatin architecture. Genes Immun 12:291-299.
• [18]Libby RT, Hagerman KA, Pineda VV, Lau R, Cho DH, Baccam SL, Axford MM, Cleary JD, Moore JM, Sopher BL, et al.: CTCF cis-regulates trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination. PLoS Genet 2008, 4:e1000257.
• [19]Sun L, Huang L, Nguyen P, Bisht KS, Bar-Sela G, Ho AS, Bradbury CM, Yu W, Cui H, Lee S, et al.: DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation. Cancer Res 2008, 68:2726-2735.
• [20]Nguyen P, Cui H, Bisht KS, Sun L, Patel K, Lee RS, Kugoh H, Oshimura M, Feinberg AP, Gius D: CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region. Cancer Res 2008, 68:5546-5551.
• [21]Jothi R, Cuddapah S, Barski A, Cui K, Zhao K: Genome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data. Nucleic Acids Res 2008, 36:5221-5231.
• [22]Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, et al.: Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005, 65:7763-7774.
• [23]Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon YW, Bosman FT, Lobanenkov V, Benhattar J: BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res
• [24]Campbell AE, Martinez SR, Miranda JJ: Molecular architecture of CTCFL. Biochem Biophys Res Commun 396:648-650.
• [25]Nguyen P, Bar-Sela G, Sun L, Bisht KS, Cui H, Kohn E, Feinberg AP, Gius D: BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression. Mol Cell Biol 2008, 28:6720-6729.
• [26]Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, et al.: BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci USA 2002, 99:6806-6811.
• [27]Ohlsson R, Lobanenkov V, Klenova E: Does CTCF mediate between nuclear organization and gene expression? Bioessays 32:37-50.
• [28]Ishihara K, Oshimura M, Nakao M: CTCF-dependent chromatin insulator is linked to epigenetic remodeling. Mol Cell 2006, 23:733-742.
• [29]Lutz M, Baniahmad A, Renkawitz R: Modulation of thyroid hormone receptor silencing function by co-repressors and a synergizing transcription factor. Biochem Soc Trans 2000, 28:386-389.
• [30]Lutz M, Burke LJ, Barreto G, Goeman F, Greb H, Arnold R, Schultheiss H, Brehm A, Kouzarides T, Lobanenkov V, Renkawitz R: Transcriptional repression by the insulator protein CTCF involves histone deacetylases. Nucleic Acids Res 2000, 28:1707-1713.
• [31]Chernukhin IV, Shamsuddin S, Robinson AF, Carne AF, Paul A, El-Kady AI, Lobanenkov VV, Klenova EM: Physical and functional interaction between two pluripotent proteins, the Y-box DNA/RNA-binding factor, YB-1, and the multivalent zinc finger factor, CTCF. J Biol Chem 2000, 275:29915-29921.
• [32]Donohoe ME, Silva SS, Pinter SF, Xu N, Lee JT: The pluripotency factor Oct4 interacts with Ctcf and also controls X-chromosome pairing and counting. Nature 2009, 460:128-132.
• [33]Jelinic P, Stehle JC, Shaw P: The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. PLoS Biol 2006, 4:e355.
• [34]Miranda TB, Miranda M, Frankel A, Clarke S: PRMT7 is a member of the protein arginine methyltransferase family with a distinct substrate specificity. J Biol Chem 2004, 279:22902-22907.
• [35]Wysocka J, Myers MP, Laherty CD, Eisenman RN, Herr W: Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1. Genes Dev 2003, 17:896-911.
• [36]Lachner M, O'Sullivan RJ, Jenuwein T: An epigenetic road map for histone lysine methylation. J Cell Sci 2003, 116:2117-2124.
• [37]Guccione E, Bassi C, Casadio F, Martinato F, Cesaroni M, Schuchlautz H, Luscher B, Amati B: Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature 2007, 449:933-937.
• [38]Brykczynska U, Hisano M, Erkek S, Ramos L, Oakeley EJ, Roloff TC, Beisel C, Schubeler D, Stadler MB, Peters AH: Repressive and active histone methylation mark distinct promoters in human and mouse spermatozoa. Nat Struct Mol Biol 17:679-687.
• [39]Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR: DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007, 7:21.
• [40]Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi KO, Karpf AR: Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011, 17:2170-80.
• [41]Dougherty CJ, Ichim TE, Liu L, Reznik G, Min WP, Ghochikyan A, Agadjanyan MG, Reznik BN: Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun 2008, 370:109-112.
• [42]Hines WC, Bazarov AV, Mukhopadhyay R, Yaswen P: BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas. PLoS One 5:e9738.
• [43]Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C: Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 2008, 122:777-784.
• [44]Woloszynska-Read A, James SR, Song C, Jin B, Odunsi K, Karpf AR: BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun 10:6.
• [45]Yoon SL, Kim DC, Cho SH, Lee SY, Chu IS, Heo J, Leem SH: Susceptibility for breast cancer in young patients with short rare minisatellite alleles of BORIS. BMB Rep 2010, 43:698-703.
• [46]Witcher M, Emerson BM: Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 2009, 34:271-284.
• [47]Soto-Reyes E, Recillas-Targa F: Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene 29:2217-2227.
• [48]Shi L, Wu J: Epigenetic regulation in mammalian preimplantation embryo development. Reprod Biol Endocrinol 2009, 7:59. BioMed Central Full Text
• [49]D'Arcy V, Pore N, Docquier F, Abdullaev ZK, Chernukhin I, Kita GX, Rai S, Smart M, Farrar D, Pack S, et al.: BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 2008, 98:571-579.
• [50]Narva E, Autio R, Rahkonen N, Kong L, Harrison N, Kitsberg D, Borghese L, Itskovitz-Eldor J, Rasool O, Dvorak P, et al.: High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol 28:371-377.
• [51]Mastracci TL, Shadeo A, Colby SM, Tuck AB, O'Malley FP, Bull SB, Lam WL, Andrulis IL: Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast. Genes Chromosomes Cancer 2006, 45:1007-1017.
• [52]van Wezel T, Lombaerts M, van Roon EH, Philippo K, Baelde HJ, Szuhai K, Cornelisse CJ, Cleton-Jansen AM: Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res 2005, 7:R998-1004. BioMed Central Full Text
• [53]Mummert SK, Lobanenkov VA, Feinberg AP: Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 2005, 43:155-161.
• [54]Smith IM, Glazer CA, Mithani SK, Ochs MF, Sun W, Bhan S, Vostrov A, Abdullaev Z, Lobanenkov V, Gray A, et al.: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 2009, 4:e4961.
• [55]Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15:5323-5337.
• [56]Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG: Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 2006, 98:1037-1043.
• [57]Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG: Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol 2007, 178:566-573.
• [58]Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG: DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther 2008, 15:61-64.
• [59]Mkrtichyan M, Ghochikyan A, Davtyan H, Movsesyan N, Loukinov D, Lobanenkov V, Cribbs DH, Laust AK, Nelson EL, Agadjanyan MG: Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol 270:188-197.
• [60]Foulkes WD: BRCA1 functions as a breast stem cell regulator. J Med Genet 2004, 41:1-5.
• [61]Brody LC, Biesecker BB: Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) 1998, 77:208-226.
• [62]Hoffmann MJ, Muller M, Engers R, Schulz WA: Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol 2006, 72:1577-1588.
• [63]Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, Gorlick R, Meyers P, Healey J, Ladanyi M, Hoffman AR: Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 2003, 12:535-549.